… , for the treatment of patients with locally advanced or … Union for maintenance therapy in
patients with locally advanced or … Prior exposure to EGFR inhibitors such as erlotinib, gefitinib, …

… by gefitinib maintenance therapy compared with patients treated with gefitinib alone. Both …
to determine whether similar results were seen in patients with confirmed EGFR mutations, but …

… -line and maintenance therapy within patient groups. Literature … +gefitinib, maintenance
gefitinib in patients clinically … chemotherapy + erlotinib with erlotinib maintenance showed the …

… The current study examines the efficacy, safety, and tolerability of ASP8273 versus
erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR …

… gene (EGFR) mutations, EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib
are the preferred first-line treatment option.3, 5 Activating EGFR mutations are common in …

… of a phase I study of combination of erlotinib and pemetrexed and two phase III trials of
combination of gefitinib and platinum doublet chemotherapy in advanced NSCLC [29–31]. We …

… for a subset of patients with advanced NSCLC with wild-type EGFR in the TORCH (Tarceva
or Chemotherapy) study. In that study, first-line treatment with the EGFR TKI erlotinib (n = 83) …

… A phase III trial was conducted to compare the safety and efficacy of erlotinib with that of
gefitinib in advanced non-small cell lung cancer harbouring epidermal growth factor receptor …

… The OS benefit from first-line treatment with dacomitinib versus gefitinib was maintained
after extended follow-up in patients with advanced NSCLC with EGFR-activating mutations. …

… gefitinib, and erlotinib for first-line treatment of patients with advanced EGFR mutation-positive
non-small-cell lung … In addition, we investigated the safety of afatinib, gefitinib, and erlotinib…